Bergen, Norway, 23[rd] October 2020 - BerGenBio ASA (OSE:BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical need, is pleased to announce that it will
host a virtual R&D Day on 06 November 2020 from 13.00 CET.

The event will feature independent experts highlighting the role of AXL kinase
as an essential mediator of the biological mechanisms underlying life
-threatening diseases. The presentations will focus on the role of AXL in
specific disease areas including oncology, fibrosis and infectious disease such
as COVID-19. Each presentation will be followed by a Q&A session.

A preliminary program for the event is outlined below. To register, please click
here (bergenbio@consilium
-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20
E
vent).

                  Preliminary Agenda
                    (times in CET)
13:00   Introduction - Richard
        Godfrey, Chief Executive
        Officer, BerGenBio

13:10   AXL in AML/MDS
        - Professor Sonja
        Loges, Director,
        Department
        of Personalised Oncology,
        University Hospital
        Mannheim and Division
        of Personalised Medical
        Oncology, German Research
        Center - DKFZ
        (Heidelberg, Germany)
13:40   AXL in lung cancer - Dr
        Matthew Krebs, Clinical
        Senior Lecturer in
        Experimental Cancer
        Medicine and Honorary
        Consultant in Medical
        Oncology, The Christie
        NHS Foundation Trust
        (Manchester, UK)
14:10   AXL and viruses/COVID-19
        - Professor Wendy Maury,
        Professor of Microbiology
        and Immunology,
        University of Iowa (Iowa
        City, USA)
14:40   AXL in fibrosis/IPF -
        Professor Cory Hogaboam,
        Professor of Medicine,
        Cedars-Sinai Medical
        Center (Los Angeles, USA)
15:10   Bemcentinib clinical
        development plan - Hani
        Gabra, Chief Medical
        Officer, BerGenBio
15:25   Concluding remarks -
        Richard Godfrey, Chief
        Executive Officer,
        BerGenBio
For further information, please contact Consilium
Strategic Communications at bergenbio@consilium
-comms.com or
i (ir@bergenbio.com)r@bergenbio.co (ir@bergenbio.com)m

- END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body's immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.